31 results about "Transferrin iron" patented technology

Modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and / or binding to the transferrin receptor.

The invention discloses a method for preparing egg white lysozyme and active protein by adopting coseparation. The method disclosed by the invention comprises the following steps of: collecting egg white at room temperature, regulating pH to be about 5.5, stirring to be uniform and then centrifuging; adding poly vinyl alcohol with the molecular weight of 200-20000 into supernate obtained by centrifuging, stirring to be uniform and then centrifuging; adding a saturated ammonium sulphate solution into the supernate obtained by centrifuging, mixing to be uniform and then centrifuging; respectively collecting supernate and subnatant which are obtained by centrifuging; carrying out ultrafiltration or dialysis treatment on the supernate to obtain high-purity egg white lysozyme; and carrying out ultrafiltration or dialysis treatment on the subnatant to obtain other high-purity active proteins which are ovalbumin and ovotransferrin mainly. The method disclosed by the invention is simple and practicable, cost is low, conditions are mild, and good quality of lysozyme can be maintained, so that the method disclosed by the invention is applicable to large-scale industrialization production; and other active proteins can also be obtained, so that production benefit is further increased.

The present invention relates to fusion proteins. The invention specifically relates to compositions and methods of Tf-based fusion proteins that demonstrate a high-level expression of transferrin (Tf)-based fusion proteins by inserting a helical linker between two protein domains.

A molecule suitable for use as an indicator of free iron levels in a biological sample, the molecule including an iron binding moeity and a signal generating moeity, wherein an intensity of the signal generated by the signal generating moeity is related to an amount of the iron bound by the iron binding moeity.

A molecule suitable for use as an indicator of free iron levels in a biological sample, the molecule including an iron binding moeity and a signal generating moeity, wherein an intensity of the signal generated by the signal generating moeity is related to an amount of the iron bound by the iron binding moeity.

The present invention provides novel naturally-processed antigenic peptides which are candidate tumor antigens in melanoma and other tumors. These antigenic peptides are presented by human MHC class II HLA-DR molecules. They originate from the translation factor eIF-4A, the IFN-gamma-inducible protein p78, the cytoskeletal protein vimentin and the iron-binding surface protein melanotransferrin. The antigenic peptides of the present invention can be used as markers in diagnosis of the respective tumors and in therapy as anti-tumor vaccines.

The invention discloses lactobacillus casei for prevention and auxiliary treatment of type II diabetes and application of the lactobacillus casei. The lactobacillus casei LCZ has a remarkable functionof preventing type II diabetes and the process of the type II diabetes can be well prevented after the lactobacillus casei intervenes for two weeks; the weight increase of a high-fat diet mice can beintervened and delayed, and the oral glucose tolerance increase induced by high-fat diet is prevented; expression of intestinal tract iron-related protein (transferrin and iron transport carrier protein) can be improved, chronic inflammation caused by endotoxin entering tissue is reduced, and then the effect of lowering the hyperglycemia level is achieved. Due to the remarkable functional characteristics of the lactobacillus casei, the lactobacillus casei has wide application value in various forms of probiotic foods, such as probiotic tabletting candies and probiotic solid beverages.

The invention provides a method for establishing a tuberculosis risk predicting model based on an iron metabolism index. The method comprises the following steps of (1), collecting and processing a sample; (2), measuring the iron metabolism index from the sample, particularly the iron metabolism comprises data of three kinds of serum iron, namely serum iron, transferring and ferritin; (3), fittinga training set by means of a neural network method for establishing the model, recording an optimal model parameter; calculating a model classifying threshold according to an ROC curve by means of averifying set, and establishing the tuberculosis risk predicting model. According to the method of the invention, data of the iron metabolism index in the sample human serum is measured; modeling analysis is performed on the three indexes by means of a neural network model; and an algorithm and the iron metabolism indexes are used for establishing a method for predicting the tuberculosis risk. Themodel has high sensitivity and high specificity and can be used for risk evaluation of the tuberculosis.

The invention discloses a protein-free culture medium for culturing microencapsulated recombinant Chinese hamster ovary (CHO) cells and a preparation method thereof. By using DMEM (dulbecco's modified eagle medium) / F12 as a basal culture medium, micromolecule substance iron salt with definite component, zinc salt, sodium selenite, sodium acetate, glutamine and glucose are added according to the characteristics of the microencapsulated cell culture. The culture medium does not influence the stability of the microcapsules, does not have insulin or transferrin in the traditional serum-free culture medium, and lowers the downstream technique and cost; and the product expression level is approximate to the culture level of the expensive specific culture medium, but the price is only one-tenth of the expensive specific culture medium. Thus, the protein-free culture medium can be used for microencapsulated recombinant CHO cells culture and protein expression, and greatly lowers the culture cost.

The invention provides a brain tumor magnetic resonance contrast agent. The contrast agent is transferrin coupled super-paramagnetic iron oxide nanoparticles and contains a physiologically acceptable diluent, wherein the diluent can be PBS (phosphate buffer solution) or normal saline; the weight / volume application ratio of the transferrin coupled super-paramagnetic iron oxide nanoparticles to the diluent is 10-20mg:1mL; the super-paramagnetic iron oxide nanoparticles can be super-paramagnetic ferric oxide nanoparticles or super-paramagnetic ferriferrous oxide nanoparticles; and the particle sizes of the super-paramagnetic iron oxide nanoparticles are 10-20nm. The contrast agent utilizes the high affinity between the transferrin and transferrin acceptors expressed on surfaces of cells to realize the targeting developing, and has the characteristics of high specificity, good selectivity, strong contrast effect, low toxic side effect, enough tissue concentration for the in-vivo imaging, and the like.

A test kit and a biomedical process is provided to estimate metals particularly non-transferrin bound iron levels (NTBI) in circulating body fluids particularly, serum. NTBI appears in serum when there is excess iron in the body. The method comprises of employing a signal generating moiety capable of complexing with iron that is a peptide like molecule having an iron binding site and also an optical signal generating functional group. The molecule is of microbial origin. The measurement is based on the alteration of optical characteristics of the probe molecule upon attachment of iron to its binding site on the molecule. Hence it generates a signal proportionate to the amount of iron available for binding and provides a direct estimate of free or unbound iron in the sample. According to this instant invention a rapid estimation method of NTBI in body fluids can be undertaken in an inexpensive way without the need of specialized expertise.

The invention provides an iron metabolism related protein marker composition for high myopia risk prediction and high myopia auxiliary diagnosis and application of the iron metabolism related protein marker composition. Specifically, the invention provides a biomarker composition composed of serum transferrin, a ferritin light chain and a ferritin heavy chain and a kit thereof, and the biomarker composition is applied to high myopia risk prediction and high myopia auxiliary diagnosis of a to-be-detected object. In addition, the invention also provides a marker composition or a method for screening candidate compounds for preventing, delaying or treating high myopia.

The invention discloses a joint separation method for lysozyme and ovotransferrin in egg white, and belongs to the technical field of protein separation and purification. The method comprises the steps that (1) the pH of egg white liquid is adjusted to 6.5-9.5, and metal-chelating cationic resin is adopted for adsorbing the lysozyme and the ovotransferrin; (2) eluant is subjected to crystallization treatment to obtain lysozyme crystals; (3) supernate after crystallization is collected, anion exchange resin is adopted for adsorption, the eluant is subjected to ultrafiltration and drying, and the ovotransferrin is obtained. The method can efficiently separate the lysozyme and the ovotransferrin from the egg white at the same time, the yield reaches 75% or above, the purity can reach 95% or above, and the adopted method has the advantages that the operation is simple, and the cost is low and is easily applied to industrialization.

The present disclosure relates to compositions and methods for treating iron overload. In particular, the methods for treating iron overload include administering to a patient an HIV protease inhibitor and an iron chelator. Iron overload may occur in patients diagnosed with anemia from inflammation or from chronic disease including hemochromatosis, sickle cell disease, thalassemia, sideroblastic anemia, an enzyme deficiency, pre-operative anemia, a cardiovascular disease, atransferrinemia, or aceruloplasminemia.

The invention provides a method for extracting protein in egg white, which mainly adopts the method of salting out precipitation combined with resin adsorption to separate ovomucin, ovotransferrin, ovalbumin, egg inhibitor, and ovomucoid from egg white at one time. and lysozyme, a total of six proteins, the method has a simple process and a short extraction period, not only avoiding the problem of toxic reagent residues, but also greatly improving production efficiency, and is easy to realize industrialization. The invention greatly improves the added value of egg processing and produces significant economic and social benefits.

The invention relates to the field of medical materials, and discloses a preparation method of OCMCS-modified iron oxide nanoparticles coupling folic acid and transferrin. The method comprises the following steps of: firstly, preparing superparamagnetic nano iron oxide particles by using iron acetylacetonate as an iron source through a high-temperature thermal decomposition method, wherein carboxymethyl chitosan has amino groups and hydroxyl groups and further modifies the surfaces of the iron oxide particles so as to obtain Fe3O4@OCMCS; then adding transferrin, and performing ultrasonic shaking table incubation to obtain Fe3O4@OCMCS-Tf; finally, adding activated folic acid, and performing reaction in the dark under strong stirring so as to obtain Fe3O4@OCMCS-Tf-FA which has multiple targeting properties.

The invention discloses a method for preparing egg white lysozyme and active protein by adopting coseparation. The method disclosed by the invention comprises the following steps of: collecting egg white at room temperature, regulating pH to be about 5.5, stirring to be uniform and then centrifuging; adding poly vinyl alcohol with the molecular weight of 200-20000 into supernate obtained by centrifuging, stirring to be uniform and then centrifuging; adding a saturated ammonium sulphate solution into the supernate obtained by centrifuging, mixing to be uniform and then centrifuging; respectively collecting supernate and subnatant which are obtained by centrifuging; carrying out ultrafiltration or dialysis treatment on the supernate to obtain high-purity egg white lysozyme; and carrying out ultrafiltration or dialysis treatment on the subnatant to obtain other high-purity active proteins which are ovalbumin and ovotransferrin mainly. The method disclosed by the invention is simple and practicable, cost is low, conditions are mild, and good quality of lysozyme can be maintained, so that the method disclosed by the invention is applicable to large-scale industrialization production; and other active proteins can also be obtained, so that production benefit is further increased.

The invention belongs to the field of genetic engineering antibody technology and cell biology technology, and specifically relates to a single-chain antibody targeting transferrin receptor (TfR) in the brain. In vitro experiments have proved that the single-chain antibody targeting transferrin receptors of the present invention can specifically bind to transferrin receptors, and can be used as a small molecule carrier for diagnosis and treatment of central nervous system diseases, and can be applied to coupling brain It is of great value to the development and research of drugs for central nervous system diseases.

The present invention provides a pharmaceutical composition comprising an iron chelating agent exhibiting antitumor activity, antimicrobial activity, and / or antivirus activity and having reduced side effects. Specifically, the present invention provides a pharmaceutical composition for use in treatment of cancer or infectious disease, comprising an iron chelating agent that selectively binds to biologically unstable iron, rather than to transferrin-bound iron.

The invention relates to the technical field of protein extraction, specifically a method for industrialized extraction of ovotransferrin and its protein iron product, which mainly uses a high-voltage pulsed electric field to assist in the treatment of egg whites to reduce viscosity and surface tension, and the molecular polarization of the electric field induces more charged electrodes Sexual groups are exposed, and the charged molecules produce repeated violent movements. This movement destroys the fibrous structure of ovomucin, disintegrates the complex formed by ovomucin and ovomucoid, lysozyme and other soluble proteins, and the thick protein is thin. The viscosity is further reduced, and the molecular dispersion plays a very good auxiliary separation effect, which is helpful for the ultrafiltration separation in the later stage and improves the protein yield; by switching to ferrous iron and ovotransferrin in egg white for chelation, not only can Enhancing the structural stability of ovotransferrin makes it possible to add high-concentration ethanol for further purification in the later stage, and it is easier for the human body to absorb ferrous iron.

The invention provides a serum-free neural precursor cell culture medium as well as a preparation method and application thereof. The serum-free neural precursor cell culture medium comprises a DMEM / F12 culture medium, non-essential amino acids, human basic fibroblast growth factors, heparin, insulin, total iron transferrin, progesterone and putrescine. When the serum-free neural precursor cell culture medium is used for culturing mesenchymal stem cells (MSCs), the efficiency of differentiating the MSCs into neural precursor cells can be improved, and the yield of the neural precursor cells is increased.

Methods and pharmaceutical compositions for optimizing intracellular iron by displacing iron bound transferrin (Tf) protein on a mammalian cell surface prior to its binding to a transferrin receptor (TfR), in the delivery of chromium chloride as being a Tf-binding agent to displace iron bound, and in the treatment of conditions involving disturbances in iron metabolism.

The invention relates to an SNP marker site related to the adaptability of horse plateau hypoxia and application thereof, and belongs to the fields of gene engineering and genetic engineering. The SNP marker is located at the 58bp of the 13th exon of a Transferrin gene of a No.16 chromosome of a horse (GAT-> AAT). The Tf gene is a hypoxia selection site of a horse, the transferrin is a carrier protein for synthesizing iron from hemoglobin, the structural function of the transferrin is related to the hemoglobin content, and the Tf gene mutant (AA) can reduce the iron carrying capacity of the horse, so that the hemoglobin concentration, the erythrocyte count and the hematocrit are reduced. The site on the Tf gene related to horse plateau hypoxia tolerance can be used as a molecular marker for horse hypoxia tolerance and plateau adaptability, and also has important significance for preservation and utilization of Tibetan horse characteristic genes.

The invention provides a method and device for synchronously separating active protein in egg white, and belongs to an active protein separation and extraction technology. The separation device formed by coupling membrane filtration and electrodialysis is used for synchronously separating and concentrating lysozyme, ovalbumin and ovotransferrin in the egg white diluent. The synchronous separation device for active protein in egg white comprises a plurality of basic working units, wherein each basic working unit has a structure of three separated chambers, including an ovalbumin recovery chamber, a feed liquid chamber and a lysozyme recovery chamber. According to the active protein synchronous separation method and device, the technical flow for separating and extracting three main active proteins, namely lysozyme, ovalbumin and ovotransferrin, in egg white is shortened, and secondary pollution caused by large consumption of chemical reagents in a multi-step salting-out method is avoided, the problem of membrane pollution in the process of pressure-driven membrane is further effectively relieved, industrial amplification is facilitated, and the purity and yield of the active protein are remarkably improved.